Challenges in the Management of Advanced Prostate Cancer

JCO Oncology Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

---

Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: March 17, 2025

Background The TALAPRO-2 trial demonstrated that the combination of talazoparib and enzalutamide significantly improved both progression-free survival (PFS) overall in patients with metastatic castration-resistant prostate cancer (mCRPC). However, cost-effectiveness this regimen remains unclear due to its high cost. This study aims evaluate compared monotherapy as a first-line treatment for mCRPC. Methods Based on data from trial, dynamic Markov model was constructed simulate disease progression mCRPC patients. From perspectives US Chinese payers, total costs, quality-adjusted life years (QALYs), incremental ratios (ICER) were considered primary outputs model. One-way sensitivity analysis probabilistic used validate robustness Price reduction provides an evidence-based basis drug pricing health insurance negotiations by quantifying impact price adjustments economics. Results In baseline analysis, ICERs plus $646,743.72/QALY $57,635.76/QALY U.S. China perspectives, respectively, which above willingness-to-pay thresholds ($150,000 $40,334 China). Sensitivity analyses showed PFS utility values prices impacted results most. adjustment scenarios needed 34.5% achieve affordability, whereas remained unaffordable even 80% reduction. Conclusion At current pricing, is not cost-effective Optimizing economic viability may be possible through genetic testing screen HRR mutation-positive populations or reduce costs. supports differentiated strategies balance clinical benefits rational allocation healthcare resources.

Language: Английский

---

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline Clinical Insights

JCO Oncology Practice, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

Language: Английский

---

Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

Language: Английский

---